DNA Methylation Levels of Melanoma Risk Genes Are Associated with Clinical Characteristics of Melanoma Patients

In melanoma development, oncogenic process is mediated by genetic and epigenetic mutations, and few studies have so far explored the role of DNA methylation either as predisposition factor or biomarker. We tested patient samples for germline CDKN2A methylation status and found no evidence of inactiv...

Full description

Saved in:
Bibliographic Details
Published inBioMed research international Vol. 2015; no. 2015; pp. 1 - 8
Main Authors Carraro, Dirce M., Krepischi, Ana C. V., Rosenberg, Carla, Campos, Antonio H. J. F. M., Achatz, Maria I., Maria-Engler, Silvya Stuchi, Pennacchi, Paula C., Kashiwabara, André Y., Pramio, Dimitrius T., de Araújo, Érica S. S., Duprat, João P.
Format Journal Article
LanguageEnglish
Published Cairo, Egypt Hindawi Publishing Corporation 01.01.2015
John Wiley & Sons, Inc
Hindawi Limited
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:In melanoma development, oncogenic process is mediated by genetic and epigenetic mutations, and few studies have so far explored the role of DNA methylation either as predisposition factor or biomarker. We tested patient samples for germline CDKN2A methylation status and found no evidence of inactivation by promoter hypermethylation. We have also investigated the association of clinical characteristics of samples with the DNA methylation pattern of twelve genes relevant for melanomagenesis. Five genes (BAP1, MGMT, MITF, PALB2, and POT1) presented statistical association between blood DNA methylation levels and either CDKN2A-mutation status, number of lesions, or Breslow thickness. In tumors, five genes (KIT, MGMT, MITF, TERT, and TNF) exhibited methylation levels significantly different between tumor groups including acral compared to nonacral melanomas and matched primary lesions and metastases. Our data pinpoint that the methylation level of eight melanoma-associated genes could potentially represent markers for this disease both in peripheral blood and in tumor samples.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Academic Editor: Rajiv Kumar
ISSN:2314-6133
2314-6141
DOI:10.1155/2015/376423